di(tert-butyl) 4-{[4-(2-butynyloxy)phenyl]sulfonyl)-1,4-diazepane-1,5-dicarboxylate | 287408-74-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: di(tert-butyl) 4-{[4-(2-butynyloxy)phenyl]sulfonyl)-1,4-diazepane-1,5-dicarboxylate
• 英文别名: Ditert-butyl 4-(4-but-2-ynoxyphenyl)sulfonyl-1,4-diazepane-1,5-dicarboxylate
• CAS: 287408-74-6
• 化学式: C₂₅H₃₆N₂O₇S
• 分子量: 508.636
• InChiKey: UJCBRSOFWWXFKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  613.5±65.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  di(tert-butyl) 4-{[4-(2-butynyloxy)phenyl]sulfonyl)-1,4-diazepane-1,5-dicarboxylate 在 盐酸 、 草酰氯 、 羟胺 、 三乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-But-2-ynyloxy-benzenesulfonyl)-1-isobutyryl-[1,4]diazepane-5-carboxylic acid hydroxyamide
  参考文献：
  名称：

  Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors

  摘要：

  Potent and selective TACE and MMP inhibitors utilizing the diazepine and thiazepine ring systems were synthesized and evaluated for biological activity in in vitro and in vivo models of TNF-α release. Oral activity in the mouse LPS model of TNF-α release was seen. Efficacy in the mouse collagen induced arthritis model was achieved with diazepine 20. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.053
• 作为产物：
  描述：

  [1,4]二氮杂烷-5-羧酸叔丁酯 在 4-二甲氨基吡啶 、 sodium hydroxide 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 di(tert-butyl) 4-{[4-(2-butynyloxy)phenyl]sulfonyl)-1,4-diazepane-1,5-dicarboxylate
  参考文献：
  名称：

  Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors

  摘要：

  Potent and selective TACE and MMP inhibitors utilizing the diazepine and thiazepine ring systems were synthesized and evaluated for biological activity in in vitro and in vivo models of TNF-α release. Oral activity in the mouse LPS model of TNF-α release was seen. Efficacy in the mouse collagen induced arthritis model was achieved with diazepine 20. © 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.053

文献信息

• Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06225311B1

  公开（公告）日：2001-05-01

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  该式化合物在治疗由TNF-α介导的疾病条件中很有用，如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。
• Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：——

  公开号：US20030008849A1

  公开（公告）日：2003-01-09

  Compounds of the formula: 1 are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  公式为1的化合物可用于治疗由TNF-&agr;介导的疾病条件，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨丢失。
• Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：Levin I. Jeremy

  公开号：US20050113346A1

  公开（公告）日：2005-05-26

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  式为的化合物在治疗由TNF-α介导的疾病条件方面非常有用，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨损失。
• ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
  申请人：Wyeth Holdings Corporation

  公开号：EP1144368B1

  公开（公告）日：2004-07-14
• US6225311B1
  申请人：——

  公开号：US6225311B1

  公开（公告）日：2001-05-01